Cancers represent complex ecosystems comprising tumor cells and a multitude of non-
cancerous cells, embedded in an altered extracellular matrix. The tumor microenvironment …

Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

In the past decade, substantial advances have been made in understanding the biology of
tumour-associated macrophages (TAMs), and their clinical relevance is emerging. A …

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the …

CD8+ T cells are critical for elimination of cancer cells. Factors within the tumor
microenvironment (TME) can drive these cells to a hypofunctional state known as …

Interleukins and associated cytokines serve as the means of communication for innate and
adaptive immune cells as well as non-immune cells and tissues. Thus, interleukins have a …

The tumor microenvironment (TME) influences cancer progression and therapy response.
Therefore, understanding what regulates the TME immune compartment is vital. Here we …

The mutational landscape of colorectal cancer (CRC) does not enable predictions to be
made about the survival of patients or their response to therapy. Instead, studying the …

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell
therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment …